Integrated BioPharma, Inc.
Integrated BioPharma, Inc. (INBP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
inbp · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Integrated BioPharma, Inc. (INBP) measures how much investors pay for each dollar of the company's trailing earnings. INBP's current PE ratio of N/A is calculated by dividing its stock price of $0.18 by its TTM earnings per share of -$0.05.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%4.1x
MedianQ3 · 75%53.7x
Max
At N/A, INBP's current P/E is lower than in 0% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Packaged Foods · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Integrated BioPharma, Inc.You INBP | $6M | N/A | — | -$0.05 |
 BAB, Inc. BABB | $7M | 10.78x | +27.8% | $0.08 |
 Merion, Inc. EWLU | $0M | N/A | — | -$0.02 |
 Hi-Great Group Holding Company HIGR | $3M | N/A | — | -$0.00 |
 Hanover Foods Corporation HNFSA | $14M | 12.31x | +45.8% | $9.10 |
 Indofood Agri Resources Ltd. INDFY | $369M | 4.79x | -43.2% | $46052.51 |
 Inter-Rock Minerals Inc. IRCKF | $16M | 5.87x | -30.4% | $0.13 |
Industry Average 4 peers with valid PE | — | 8.44x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 13.39x | $0.03 | -75.1% | |
2024-06-30 FY2024 | 53.69x | $0.00 | — | |
2023-06-30 FY2023 | — | $-0.00 | — | |
2022-06-30 FY2022 | 3.89x | $0.13 | -4.7% | |
2021-06-30 FY2021 | 4.08x | $0.27 | +25.9% | |
2020-06-30 FY2020 | 3.24x | $0.14 | +2.2% | |
2019-06-30 FY2019 | 3.17x | $0.06 | -54.1% | |
2018-06-30 FY2018 | 6.90x | $0.02 | +303.6% | |
2017-06-30 FY2017 | 1.71x | $0.11 | -29.4% | |
2016-06-30 FY2016 | 2.42x | $0.05 | -0.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Integrated BioPharma, Inc. (INBP) measures how much investors pay for each dollar of the company's trailing earnings. INBP's current PE ratio of N/A is calculated by dividing its stock price of $0.18 by its TTM earnings per share of -$0.05.
Frequently asked questions
INBP pe ratio · 6 questionsINBP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.18 and TTM EPS of -$0.05. Data sourced from Financial Modeling Prep via INBP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Integrated BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08